Expertise in
23
conditions

Dr. Gregory Daniels

Hematology | Oncology
Ucsd Health Moores Cancer Center
3855 Health Sciences Dr, 
La Jolla, CA 
Offers Telehealth
Expertise in
23
conditions
Ucsd Health Moores Cancer Center
3855 Health Sciences Dr, 
La Jolla, CA 

Overview

Gregory Daniels is a Hematologist and an Oncologist practicing medicine in La Jolla, California.

Dr. Daniels is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Melanoma, Follicular Thyroid Cancer, Thyroid Cancer, Oral Squamous Cell Carcinoma, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 80 peer reviewed articles and participating in 17 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Uc San Diego Health Hillcrest - Hillcrest Med Ctr

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Ucsd Health Moores Cancer Center
3855 Health Sciences Dr, La Jolla, CA 92093
Other Locations
UCSD Heath Care
3855 Health Sciences Dr, La Jolla, CA 92093
Office
200 W Arbor Dr, San Diego, CA 92103

Additional Areas of Focus

Dr. Daniels has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
Enrollment Status: Terminated
Publish Date: August 06, 2026
Intervention Type: Drug
Study Drug: IL-2 and Nivolumab
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)
An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2026
Intervention Type: Biological
Study Drug: RP1 Genetically-Modified Herpes Simplex Type 1 Virus
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2026
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
Study Phase: Phase 2
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Enrollment Status: Completed
Publish Date: October 01, 2024
Intervention Type: Drug
Study Phase: Phase 1
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Selumetinib, Iodine-131
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Biological
Study Drug: ITIL-168
Study Phase: Phase 2
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug, Biological
Study Drugs: Cetuximab, PD 0332991
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

80 Total Publications

High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
Journal: Melanoma research
Published: February 04, 2026
Similar Doctors
Expertise in
24
conditions
Dr. James I. Geller
Hematology | Oncology
Expertise in
24
conditions
Dr. James I. Geller
Hematology | Oncology
Referral may be required

Rady Children's Hospital San Diego

3020 Childrens Way, 
San Diego, CA 
 (3.2 miles away)
858-966-5811
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Geller is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Geller is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Wilms Tumor, Hepatoblastoma, Renal Cell Carcinoma (RCC), Nephrectomy, and Bone Marrow Aspiration. Dr. Geller is currently accepting new patients.

Expertise in
10
conditions
Dr. Courtney D. Thornburg
Hematology | Oncology
Expertise in
10
conditions
Dr. Courtney D. Thornburg
Hematology | Oncology
Referral may be required

Office

3010 Childrens Way, 
San Diego, CA 
 (3.1 miles away)
858-966-8035
Languages Spoken:
English
See accepted insurances

Courtney Thornburg is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Thornburg is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Hemophilia A, Blood Clots, Sickle Cell Disease, Hemolytic Anemia, and Splenectomy.

Expertise in
4
conditions
Dr. Peter E. Zage
Hematology | Oncology
Expertise in
4
conditions
Dr. Peter E. Zage
Hematology | Oncology
Referral may be required

Rady Children's Hospital San Diego

3020 Childrens Way, 
San Diego, CA 
 (3.2 miles away)
858-966-5811
Languages Spoken:
English
See accepted insurances

Peter Zage is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Zage is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Neural Crest Tumor.

Frequently Asked Questions about Dr. Gregory Daniels

How do I make an appointment with Dr. Gregory Daniels?

You can book an appointment with Dr. Gregory Daniels by calling their office at 858-822-6100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gregory Daniels a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gregory Daniels is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gregory Daniels specialize in?

While Dr. Gregory Daniels is a Hematology, they have specific expertise in Melanoma, Follicular Thyroid Cancer, and Thyroid Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Gregory Daniels participate in research or clinical trials?

Yes. Dr. Gregory Daniels has published 80 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Gregory Daniels's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gregory Daniels accept my insurance?

Dr. Gregory Daniels accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 858-822-6100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Daniels's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile